Uterine fibroids are a major cause of morbidity in women of a reproductive age. The management of symptomatic fibroids has traditionally been surgical. However, USFDA recently approved ulipristal acetate, an oral selective progesterone-receptor modulator, for the same indication. Ulipristal acetate is a new, effective, and well-tolerated option for the preoperative treatment of moderate and severe symptoms of uterine fibroids in women of reproductive age. Clinical data shows ulipristal acetate has several advantages: it acts faster in reducing the fibroid-associated bleeding, it significantly improves hemoglobin and hematocrit levels in anemic patients, and it grants a significant reduction in the size of fibroids.